After initially serving as a proving ground for integrating forward engineering principles into living cells, synthetic biology is making waves across diverse therapeutic areas. In this article, Dr Dan Mandell, Co-Founder and CEO of GRO Biosciences, explains how the field is reshaping our understanding of the limits of cell- and molecular-based medicines.
List view / Grid view
Warp Drive Bio
11 January 2016 | By Victoria White
The collaboration will focus on the development of drugs targeting important human oncogenes, including RAS, and new antibiotics targeting Gram-negative bacteria...